
Stay on Offense. Play the Long Game. Strategic communications partner to the life sciences industry, founded by @DanBudwick
Tampa, FL
Joined April 2017
- Tweets273
- Following206
- Followers498
- Likes95
Another afternoon at the Food Bank in the books! The 1AB team spent the afternoon helping prepare 1,200 meals for neighbors in need at the @FoodBankCENC. Always grateful for the opportunity to roll up our sleeves and give back!
We're at the @NYSE today with the team at @StructureTx for their live segment on @CNBC. Structure is on a mission to develop more accessible oral small molecule therapeutics for the treatment of #obesity. We're proud to play a small role in bringing their mission to life. $GPCR
Busy week at the Cowen Health Care Conference! It’s always a pleasure to check in with our clients & connect with leaders who are shaping the future of healthcare. Events like this remind us how fast this industry is evolving & how important collaboration is in driving progress.
In NYC for the inaugural #CNBCCures Summit! 💜
We were humbled to attend such an impactful event which brings together the most influential leaders in #biotech to accelerate the future of medicine through breakthroughs in #raredisease research.
Join us in wishing our founder and CEO @DanBudwick a very happy birthday! We're grateful for all you do to inspire our team, lead with vision, and build a company we’re proud to be part of. Cheers to another great year ahead! 🎉
1AB retweeted
Kicking off #JPM26 - @BridgeBioPharma $BBIO CEO Neil Kumar & team continue to deliver. Strong sales ramp for Attruby; 6,628 unique patient scrips written by 1,632 prescribers at yr end. 2 NDA submissions 1H 26. Phase 3 achon data Q1 26. Full update here: investor.bridgebio.com/news/…
1AB retweeted
Packed house for @MazeInBiotech $MAZE CEO @jcmazer as he provides a pipeline update and look ahead at milestones for the yr at #JPM26; you can view the presentation here: ir.mazetx.com/static-files/6…
1AB retweeted
Up now at #JPM26 - @insitro founder/CEO @DaphneKoller discusses its full stack, modality-agnostic, AI-driven capability - leveraging small molecules, oligonucleotides, antibodies & other biologics with precision–enabling biology to guide target discovery and molecular design.
1AB retweeted
Next up at #JPM26 - @STAR_Biotech Founder/CEO Adam Rosenthal provides overview on co and lead program VGA039, a first-in-class mAb that has potential to be a universal hemostatic therapy addressing numerous bleeding disorders, starting w/ VWD (currently in pivotal Phase 3 study).





























